WASHINGTON – The biotech industry has long appreciated the value of partnership, but biomarker development is taking collaboration to a new level. It is not possible to develop good and useful biomarkers without involving academics, having access to patients, expertise in sequencing, molecular diagnostics platforms, bioinformatics and the cooperation of clinicians and regulators.